Email updates

Keep up to date with the latest news and content from BMC Gastroenterology and BioMed Central.

Open Access Research article

Hereditary risk factors for the development of gastric cancer in younger patients

Mohammad Yaghoobi*, Naser Rakhshani, Farhad Sadr, Raheleh Bijarchi, Yasamin Joshaghani, Ashraf Mohammadkhani, Arezou Attari, Mohammad Reza Akbari, Mahshid Hormazdi and Reza Malekzadeh

BMC Gastroenterology 2004, 4:28  doi:10.1186/1471-230X-4-28

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Oncological terrain plays a paramount role in the war against cancer-.

Sergio Stagnaro   (2004-10-30 14:42)  Private. Specialist in Blood, Gastroenterological, and Metabolic Diseases. Researcher in Biophysical Semeiotics. email

Sirs,

I agry with paper's authors, but from the clinical view-point ( Hereditary risk factors for the development of gastric cancer in younger patients. Mohammad Yaghoobi , Nasser Rakhshani , Farhad Sadr , Raheleh Bijarchi , Yassamin Joshaghani , Ashraf Mohammadkhani , Arezu Attari , Mohammad reza Akbari , Mahshid Hormazdi and Reza Malekzadeh

BMC Gastroenterology 2004, 4:28 doi:10.1186/1471-230X-4-28.

Really in the war against cancers, we must especially study a clinical tool that helps “all” doctors in bed side recognizing, in apparently healthy individuals, genetical errors, including hyperinsulinemia-insulinresistance, melatonine deficiency, metabolic disorders, prevalence of stress axis, a.s.o., which either bring about or aggravate environmental chromosomal aberrations as those observed in cancer cells. In fact, our target can be reached hopefully if “all” doctors are able to ascertain or at least suspect at the bed-side in apparently healthy person chromosomal aberrations, before cancer on-set.

As a working hypothesis, I thought 20 years ago that all parenchimal chromosomal alterations, of whatever nature, are necessarily accompanied with similar microvascular modification of the local microcirculatory bed, both structural and functional in nature, in subject involved by abnormalities of pschyco-neuro-endocrinological-immune system, I termed Oncological Terrain (6) (See: Oncological Terrain on my website, HONCode ID, N. 233736, www.semeioticabiofisica.it). As a matter of fact, both genetical and environmental factors induce contemporaneously parenchymal and microvascular cells alterations, according to the well-known concept of Tiscedorf’s “Angiobiotopy”, I enlarged to "Angiobiopathy (6). For instance, a family of molecules called cyclins was descovered. It is through changes in the production of cyclins during the cell cycle that the activity of the genes controlling it are themselves regulated. All these events (control, regulation a.s.o.), however, can happen only by means of changes in local microcirculation, i.e., in information-material-energy supply to tissue. Now, fortunately, thanks to Biophysical Semeiotics (See the above cited-site), we can evaluate clinically microcirculatory bed structure and function in a precise manner (2-6).

Based on 45-year-long "clinical" experience, the decline in cancer rates all over the world could be more intense if scientists will think over and discuss the possibility that exists the "Oncological Terrain". As a matter of fact, e.g., not all smokers are involved by pulmonary cancer, as well as not all people with chronic hepatitis will die of hepatocarcinoma. On the other side, in some families malignancies occur more frequently than in others. Actually, as I described in the above-mentioned papers, there are other causes that accounts for the reason of existence of the oncological “real” risk, i.e. oncological terrain.

At this point, the first question is the following: "What does characterize oncological terrain from the "clinical" point of view?". In fact, in order to achieve efficacious cancer prevention on very large scale it is unavoidable that the modifications occurring in the biological controll system could be easily, promptly, and “quantitatively” ascertained and properly evaluated with the aid of a “clinical” method, i.e. by the use of a sthetoscope, and certainly without application of sophysticated semeiotics, that does not apply in all individuals, on a very large scale, and, moreover, only a few doctors can utilize them.

If it is possible to answer this first question, a second one immediately follows: "The oncological terrain which certanly can be induced, is also in some way reversible?" It is urgent and necessary to know if the oncological terrain can be reversed, i.e. if it can totally or greatly disappeare, with the aid of drugs or diet, ethymologically speaking, which exert a favourable influence on the characteristic modifications of the psicho-neuro-endocrine- immunological system, that represent “oncological terrain”. My answers to these questions are readable in my site (5, 6).

The war against cancer will be fortunately won if all doctor are going to recognize, with the aid of a stethoscope, individual apparently health but positive for “oncological terrain”, particularly intense in a well defined tissue region, who have to undergo immediately to proper diet, ethymologically speaking, and drugs, in some cases. The knowledge of such as oncological predisposition will certainly help us in malignancy primary prevention, firstly selecting individuals at real oncological risk.

1) Watts G. Three cell cycle scientists win Nobel prize. BMJ 2001; 323:823 (13 October).

2) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica del torace, della circolazione ematica e dell’anticorpopoiesi acuta e cronica. Acta Med. Medit. 13, 25 1997

3) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125 1997

4) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: valutazione clinica del picco precoce della secrezione insulinica di base e dopo stimolazione tiroidea, surrenalica, con glucagone endogeno e dopo attivazione del sistema renina-angiotesina circolante e tessutale – Acta Med. Medit. 13, 99.

5) Stagnaro S., Sindrome percusso-ascoltatoria di Iperfunzione del Sistema Reticolo-Istiocitario. Min. Med. 74, 479, 1983 (Pub-Med indexed for Medline)

6) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. www.travelfactory.it

Competing interests

No declared

top

Post a comment